A team of researchers has presented promising results from an early-stage clinical trial aimed at slowing the progression of diseases such as Alzheimer's and Parkinson's. The treatment, based on a molecule that regulates neuronal inflammation, managed to reduce synapse loss in a small group of patients. Although the sample is small, the data opens a path for future, more specific therapies.
Mechanism of action: how the molecule halts cellular damage 🧠
The compound acts on the TREM2 protein, present in the microglial cells of the brain. By activating this protein, the elimination of toxic waste such as beta-amyloid plaques and tau tangles is promoted. In animal models, a 40% reduction in the accumulation of these aggregates was observed. Human trials partially replicated these effects, with an improvement in neuroinflammation markers and no serious adverse effects reported.
The brain appreciates it, though the wallet not so much 💸
As expected, the next step will be to request funding for a larger phase. And here comes the drama: the development costs of a neurological drug can exceed one billion euros. But hey, if they manage to make us remember where we left our keys for more than five minutes, it might be worth it. Of course, let's hope they don't raise the price of coffee in the meantime, or we'll have a fit.